CRANBURY, N.J. Amicus Therapeutics and Shire Human Genetics Therapy have entered into a collaboration to jointly develop Amicus’ three lead pharmacological chaperone compounds for lysosomal storage disorders.
The collaboration includes the drugs: Amigal for the treatment of Fabry disease, Plicera, which is used to treat Gaucher disease, and AT2220 which is used to treat Pompe disease. Amigal and Plicera are in Phase 2 clinical trials, while AT2220 is in Phase 1 clinical trials.
Under the terms of the deal, Amicus will receive an initial, licensing payment of $50 million. Joint development costs toward global approval of the three compounds will be shared equally going forward, and Amicus is eligible to receive an additional $150 million if certain clinical and regulatory milestones are met for the three programs through approvals. Amicus is also eligible to receive up to $240 million in sales-based milestones, as well as tiered double-digit royalties. Not including royalties and cost sharing, the deal is valued at up to $440 million.